Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors
- 23 February 2025
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (4) , 194-202
Abstract
Study Objective: The primary objective of this study was to determine if there was a significant change in potassium levels with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor therapy in people with type 2 diabetes (T2D). A co‐primary objective was to evaluate which factors may predispose a patient to changes in potassium levels. Design: Multicenter retrospective cohort chart review. Data Source: Study patients were identified through an electronic medical record‐generated report if they had T2D and were prescribed an SGLT2 inhibitor from January 2013 to September 2019. Patients: Patients were included if they had T2D, were receiving care at Advocate Medical Group, and were confirmed to have taken one of the four SGLT2 inhibitors available at the time of study approval, canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin, for at least 7 days. Patients were excluded if they did not have a basic metabolic panel or comprehensive metabolic panel recorded 1 year prior to or 6 months after SGLT2 inhibitor therapy initiation. Results: Data extraction from the electronic medical record identified 6425 patients receiving an SGLT2 inhibitor, of which 1926 met inclusion criteria. The SGLT2 inhibitor most prescribed was canagliflozin (43.7%), followed by empagliflozin (36.9%) and dapagliflozin (19.4%). Concomitant baseline medications were thiazide diuretics (27.5%); angiotensin‐converting enzyme inhibitors, angiotensin II receptor blockers, or angiotensin receptor‐neprilysin inhibitors (72.1%); and/or mineralocorticoid receptor antagonists (27.2%). A statistically significant change in potassium levels was found with dapagliflozin ( p = 0.018); albeit not clinically significant. No other statistically significant changes or patterns were identified. The overall mean change in serum potassium from baseline was 0.021 mmol/L within 3 months; 0.007 mmol/L from 3 to 5.9 months; −0.017 mmol/L within 6–12 months; and 0.004 mmol/L after more than 12 months. Conclusions: No clinically significant increase or decrease in potassium levels was observed upon initiation of SGLT2 inhibitor therapy in patients with T2D. This was consistent across background medication use and patient‐specific factors. Baseline potassium should not be a factor in initiating SGLT2 inhibitor therapy, if clinically indicated, in patients with T2D.Keywords
This publication has 18 references indexed in Scilit:
- Identification of risk factors associated with acute kidney injury in patients taking sodium‐glucose cotransporter‐2 inhibitorsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- Effect of sodium-glucose co-transporter 2 inhibitors on plasma potassium: A meta-analysisDiabetes Research and Clinical Practice, 2023
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney DiseaseKidney International, 2022
- Dapagliflozin in Patients with Chronic Kidney DiseaseNew England Journal of Medicine, 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine, 2020
- Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) ProgramClinical Kidney Journal, 2020
- Best practices for safe use of SGLT-2 inhibitors developed from an expert panel Delphi consensus processAmerican Journal of Health-System Pharmacy, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2019
- Influence of glucagon on plasma levels of potassium in manDiabetologia, 1980